Stay updated on Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedLocations now include Pennsylvania, adding essential site information; the revision is updated to v3.3.3 and the previous Pennsylvania Locations entry and HHS Vulnerability Disclosure are removed.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedThe page now shows Revision: v3.3.2 in the footer, replacing the previous Revision: v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedThe banner about a lapse in government funding has been removed from the page. This notice did not affect the study details or participation requirements.SummaryDifference0.4%

- Check65 days agoChange DetectedResults have been posted (Results First Posted 2025-07-20) with updated primary and secondary outcomes and safety data.SummaryDifference0.5%

- Check93 days agoChange DetectedSignificant update: new operating-status notice and version bump to v3.2.0; previous v3.1.0 tag removed. Core content impacted by the new status information.SummaryDifference3%

- Check100 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Head & Neck Squamous Cell Cancer Clinical Trial page.